<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633398</url>
  </required_header>
  <id_info>
    <org_study_id>ASIAN HF Registry</org_study_id>
    <nct_id>NCT01633398</nct_id>
  </id_info>
  <brief_title>ASIAN HF Registry, A Prospective Observational Study</brief_title>
  <acronym>ASIANHF</acronym>
  <official_title>Asian Sudden Cardiac Death in Heart Failure(ASIAN-HF) Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolyn Lam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational &amp; Clinical Research by NMRC Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ATTRaCT program by A*STAR BMRC Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Health System, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ASIAN HF Registry is the first prospective multinational Asian registry of patients with&#xD;
      symptomatic HF (stage C) including both HFrEF (ejection fraction &lt;40%) and HFpEF (ejection&#xD;
      fraction ≥50%), with the broad purpose of determining the mortality (incidence) burden of HF&#xD;
      in Asian patients, and more specifically to define the burden and risk factors of Sudden&#xD;
      Cardiac Deaths (SCD), as well as the sociocultural barriers to preventive device therapy. The&#xD;
      study further aim to study the genetic variants associated with HFrEF versus HFpEF in our&#xD;
      large Asian cohort.&#xD;
&#xD;
      This proposed registry is expected to advance fundamental understanding of the burden and&#xD;
      predictors of preventable death among Asian patients with HF. The knowledge gained will be&#xD;
      critical for guiding resource allocation and planning preventive strategies to address the&#xD;
      unmet and growing clinical needs of patients with cardiovascular disease in Asia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a major public health problem worldwide. As the final common pathway of&#xD;
      a myriad of heart diseases, HF burden increases with increasing prevalence of cardiovascular&#xD;
      disease in a community, as patients survive their acute cardiac conditions (such as heart&#xD;
      attacks) and progress to chronic HF. Further, HF is a debilitating and deadly condition with&#xD;
      high rehospitalization rates and dismal survival rates comparable to most cancers. In&#xD;
      Singapore alone, the age-adjusted HF admission rate rose by ~40% over the last decade,1&#xD;
      making HF the commonest cardiac cause of hospitalization (representing ~24% of all cardiac&#xD;
      admissions), and the 5-year survival rate in patients with HF is only 32%. These alarming&#xD;
      statistics reflect the global shift in cardiovascular disease burden to developing countries&#xD;
      in Asia. In fact, the World Health Organization has projected that the largest increases in&#xD;
      cardiovascular disease worldwide are occurring in Asia, due to rapidly increasing rates of&#xD;
      smoking, obesity, dyslipidemia and diabetes among Asians. Thus the burden of HF is expected&#xD;
      to reach epidemic proportions in Asia. Yet in sharp contrast to the wealth of data regarding&#xD;
      HF in Western nations, epidemiologic data are scarce in Asian patients with HF.&#xD;
&#xD;
      The study will involve 46 top medical centers across 11 Asian regions (Korea, Thailand,&#xD;
      Indonesia, Philippines, India, Japan, Malaysia, Hong Kong, China, Taiwan and Singapore). Site&#xD;
      selection targeted a mix of centers covering a broad spectrum of medical, cardiology and HF&#xD;
      specialty units regularly admitting patients with acute HF and following outpatients with&#xD;
      chronic HF, constituting a novel network of Asian centers of cardiovascular expertise.&#xD;
&#xD;
      Data collection will include demographic variables, clinical symptoms, functional status,&#xD;
      date of HF diagnosis and prior cardiovascular investigations, clinical risk factors,&#xD;
      lifestyle factors, socioeconomic status, and survey of cultural beliefs, health practices and&#xD;
      attitudes towards device therapy. Center-level characteristics (caseload, referral pattern,&#xD;
      specialization, infrastructure) will also be obtained. Patients will undergo standard 12-lead&#xD;
      electrocardiography and transthoracic echocardiography at baseline, and followed over 3 years&#xD;
      for outcomes of death or hospitalization. Each outcome event and its cause will be&#xD;
      adjudicated by a central committee using pre-specified criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause and Cause-specific Death</measure>
    <time_frame>2 years follow up</time_frame>
    <description>The incidence of all-cause and cause-specific deaths among Asian patients with HF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sudden Cardiac Death</measure>
    <time_frame>2 years follow up</time_frame>
    <description>The incidence of sudden cardiac death (SCD) in eligible Asian patients diagnosed with HFrEF</description>
  </secondary_outcome>
  <enrollment type="Actual">6329</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Saliva Genetic testing</intervention_name>
    <description>To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective, observational, multinational, multicenter Asian registry of patients&#xD;
        with Stage C HF, including both HFrEF (ejection fraction &lt;40%) and HFpEF (ejection fraction&#xD;
        ≥50%).&#xD;
&#xD;
        This study population (Stage C HF) was selected in recognition of current recommendations&#xD;
        emphasizing that HF is a progressive, staged disease.The HFrEF population was defined based&#xD;
        on a recent meta-analysis showing that risk of death in HF increases particularly as&#xD;
        ejection fraction falls below 40%. The HFpEF population was defined according to current&#xD;
        guidelines. Patients with an ejection fraction in the range of 40% to 50% represent an&#xD;
        intermediate group which was not included since we aimed to study distinct clinical&#xD;
        phenotypes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (&gt;18 years)&#xD;
&#xD;
          2. Symptomatic HF (Stage C HF regardless of functional status). Patients should have a&#xD;
             current diagnosis of symptomatic HF within 6 months of an episode of decompensated&#xD;
             heart failure*, which either: (a) resulted in a hospital admission (primary diagnosis)&#xD;
             or b) was treated in out-patient clinic&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt;40% (HFrEF) or left ventricular ejection fraction&#xD;
             ≥50% (HFpEF) on baseline echocardiography&#xD;
&#xD;
          4. Available for follow-up over 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe valve disease as the primary cause of HF&#xD;
&#xD;
          2. For the HFpEF population: a documented history of reduced ejection fraction (&lt;50%) at&#xD;
             any time prior to recruitment, In other words, patients with current HFpEF who&#xD;
             previously had HFrEF will be excluded.&#xD;
&#xD;
          3. Life threatening co-morbidity with life expectancy of &lt;1 year&#xD;
&#xD;
          4. Unable or unwilling to give consent&#xD;
&#xD;
          5. Concurrent participation in a clinical therapeutic trial which requires patient&#xD;
             consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Lam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Heart Center (NUHC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta The Medicity</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cardiovascular Centre Harapan Kita Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manila Doctors Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Heart Center</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Ng TP, Niti M. Trends and ethnic differences in hospital admissions and mortality for congestive heart failure in the elderly in Singapore, 1991 to 1998. Heart. 2003 Aug;89(8):865-70.</citation>
    <PMID>12860859</PMID>
  </reference>
  <reference>
    <citation>Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90. doi: 10.1016/j.jacc.2008.11.013. Erratum in: J Am Coll Cardiol. 2009 Dec 15;54(25):2464.</citation>
    <PMID>19358937</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <results_first_submitted>April 3, 2020</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National University Health System, Singapore</investigator_affiliation>
    <investigator_full_name>Carolyn Lam</investigator_full_name>
    <investigator_title>Senior Consultant, National Heart Centre Singapore and Professor, Duke-National University of Singapore</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT01633398/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HFrEF</title>
          <description>ejection fraction &lt;40%</description>
        </group>
        <group group_id="P2">
          <title>HFpEF</title>
          <description>ejection fraction ≥50%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4779"/>
                <participants group_id="P2" count="1550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4779"/>
                <participants group_id="P2" count="1550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HFrEF</title>
          <description>ejection fraction &lt;40%</description>
        </group>
        <group group_id="B2">
          <title>HFpEF</title>
          <description>ejection fraction ≥50%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4779"/>
            <count group_id="B2" value="1550"/>
            <count group_id="B3" value="6329"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2914"/>
                    <measurement group_id="B2" value="577"/>
                    <measurement group_id="B3" value="3491"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1865"/>
                    <measurement group_id="B2" value="973"/>
                    <measurement group_id="B3" value="2838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1089"/>
                    <measurement group_id="B2" value="762"/>
                    <measurement group_id="B3" value="1851"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3690"/>
                    <measurement group_id="B2" value="788"/>
                    <measurement group_id="B3" value="4478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Chinese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1242"/>
                    <measurement group_id="B2" value="726"/>
                    <measurement group_id="B3" value="1968"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1591"/>
                    <measurement group_id="B2" value="517"/>
                    <measurement group_id="B3" value="2108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Malay</title>
                  <measurement_list>
                    <measurement group_id="B1" value="657"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="752"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1287"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="1496"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>Classification of patients' heart failure according to the severity of their symptoms.&#xD;
Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Comfortable at rest. Class III: Marked limitation of physical activity. Comfortable at rest. Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I/II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2752"/>
                    <measurement group_id="B2" value="843"/>
                    <measurement group_id="B3" value="3595"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III/IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1576"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="1854"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not assessed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                    <measurement group_id="B2" value="429"/>
                    <measurement group_id="B3" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause and Cause-specific Death</title>
        <description>The incidence of all-cause and cause-specific deaths among Asian patients with HF.</description>
        <time_frame>2 years follow up</time_frame>
        <population>Patients with outcomes available at 1 year were examined for all-cause and cardiovascular (CV) death. Patients who were lost to follow-up were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HFrEF</title>
            <description>ejection fraction &lt;40%</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>ejection fraction ≥50%</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause and Cause-specific Death</title>
          <description>The incidence of all-cause and cause-specific deaths among Asian patients with HF.</description>
          <population>Patients with outcomes available at 1 year were examined for all-cause and cardiovascular (CV) death. Patients who were lost to follow-up were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4737"/>
                <count group_id="O2" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sudden Cardiac Death</title>
        <description>The incidence of sudden cardiac death (SCD) in eligible Asian patients diagnosed with HFrEF</description>
        <time_frame>2 years follow up</time_frame>
        <population>ESC guidelines recommend an implantable cardioverter-defibrillator (ICD) device for primary prevention in symptomatic patients with heart failure with reduced ejection fraction (HFrEF), provided they are expected to survive substantially longer than one year with good functional status.&#xD;
For this outcome measure, only HFrEF patients who were eligible for ICD devices were included; HFpEF patients were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>HFrEF</title>
            <description>ejection fraction &lt;40%</description>
          </group>
          <group group_id="O2">
            <title>HFpEF</title>
            <description>ejection fraction ≥50%</description>
          </group>
        </group_list>
        <measure>
          <title>Sudden Cardiac Death</title>
          <description>The incidence of sudden cardiac death (SCD) in eligible Asian patients diagnosed with HFrEF</description>
          <population>ESC guidelines recommend an implantable cardioverter-defibrillator (ICD) device for primary prevention in symptomatic patients with heart failure with reduced ejection fraction (HFrEF), provided they are expected to survive substantially longer than one year with good functional status.&#xD;
For this outcome measure, only HFrEF patients who were eligible for ICD devices were included; HFpEF patients were excluded.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3240"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years follow up</time_frame>
      <desc>Only all-cause mortality was reported. Other adverse event not applicable as this was an observational study with no Investigation product to be assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>HFrEF</title>
          <description>ejection fraction &lt;40%</description>
        </group>
        <group group_id="E2">
          <title>HFpEF</title>
          <description>ejection fraction ≥50%</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="500" subjects_at_risk="4737"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1114"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="500" subjects_at_risk="4737"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>All-cause mortality</description>
                <counts group_id="E1" events="500" subjects_affected="500" subjects_at_risk="4737"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="1114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Acknowledgement of funding: National Medical Research Council of Singapore (R-172-003-219-511), A*STAR Biomedical Research Council Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) program (SPF2014/003, SPF2014/004, SPF2014/005), Boston Scientific Investigator Sponsored Research Program and Bayer.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carolyn Lam</name_or_title>
      <organization>National University Health System, Singapore</organization>
      <phone>(65)67048965</phone>
      <email>carolyn.lam@duke-nus.edu.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

